Abstract 214P
Background
Small cell lung cancer (SCLC) is currently treated with a combination of chemotherapy and immunotherapy. Unfortunately, not all patients benefit from this regimen and few alternative therapies are available. Based on recent transcriptomic data defining an “inflamed” subtype of SCLC patients who benefit from immunotherapy, we hypothesised that innate immune activation and natural killer (NK) cells may provide an opportunity to evaluate immune-responsive patients.
Methods
SCLC patients receiving two cycles of chemo-immunotherapy were divided into best responders (BR) and non-responders (NR). NK cells from SCLC patients (n=10) were isolated from peripheral blood-collected PBMCs and subjected to RNA-seq and gene set enrichment analysis (GSEA). Isolated NK cells were in vitro treated with DNA-dependent protein Kinase (DNA-PK) inhibitor. RT-PCR, Seahorse assay and flow cytometry were performed to investigate immune checkpoint expression.
Results
GSEA analysis of RNAseq data on NK cells from BR patients of SCLC cohorts showed high levels of IFN-related pathways (IFN_GAMMA_RESPONSE NES=2.77; p<0.0001, IFN_ALPHA_RESPONSE NES=2.49; p<0.0001) and Influenza infection (NES=3.57; p<0.0001) enrichment in BR patients derived NK cells in comparison to NR patients. In addition, NK cells from BR patients showed enrichment in oxidative phosphorylation genes (NES=2.14; p<0.0001) as well as DNA repair pathway (NES=2.07; p<0.0001). ISMARA analysis revealed that BR patients-derived NK cells showed high Interferon regulatory factor 3 (IRF3)-binding motif (Pearson corr. coeff. = 0.76; p<0.0001) compared to the NR cohort. In vitro treatment of NK cells with DNA-PKi significantly increased multiple innate immunity cytosolic DNA/RNA sensors, namely cGAS-STING (p < 0.0001), MAVS (p < 0.0001) and IFI16 (p < 0.0001). Finally, metabolic analysis showed an increase in ATP production Rate and phenotypic characterization by flow cytometry showed an increase in ICOS (CD278) expression in DNA-PKi- treated NK cells.
Conclusions
Comprehensive transcriptomic analysis of SCLC-isolated NK cells revealed significant positive modulation of innate immune pathways, suggesting a potential role for DNA-PKi in metabolic and phenotypic remodelling.
Legal entity responsible for the study
The authors.
Funding
Associazione Italiana per la Ricerca sul Cancro (AIRC).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
63P - Single-cell RNA-seq combined with bulk RNA-seq revealed the involvement of pancreatic cancer tissue-resident macrophages in tumour progression and the immunotherapy response
Presenter: Bin Wu
Session: Poster Display session
Resources:
Abstract
64P - Gene-editing of T cells to provide resistance against macrophage-mediated suppression: setting up an in vitro model
Presenter: Rui Coelho
Session: Poster Display session
Resources:
Abstract
68P - Real-world outcomes of nivolumab and/or ipilimumab in patients with stage III-IV melanoma, MELIOR study
Presenter: Ainara Soria Rivas
Session: Poster Display session
Resources:
Abstract
69P - Dose-dependent detrimental effect of proton pump inhibitors (PPIs) on clinical outcomes from immune checkpoint inhibitors (ICI) in patients (pts) with solid tumors
Presenter: elena speziale
Session: Poster Display session
Resources:
Abstract
70P - Efficacy of PD-1 blockade plus chemotherapy in patients with oncogenic-driven non-small cell lung cancer
Presenter: Haowei Wang
Session: Poster Display session
Resources:
Abstract
71P - Discontinuation of immune checkpoint inhibitors for reasons other than disease progression and the impact on relapse and survival of advanced melanoma patients: A systematic review and meta-analysis
Presenter: Konstantinos Lallas
Session: Poster Display session
Resources:
Abstract
72P - Concurrent local therapy (CLT) extends clinical benefit of tebentafusp (tebe) in metastatic uveal melanoma (mUM) patients (pts)
Presenter: Tristan Lim
Session: Poster Display session
Resources:
Abstract
73P - Impact of Assessment-to-Treatment Interval on the Predictive Value of PD-L1 Expression in Melanoma
Presenter: Cecilie Vestergaard
Session: Poster Display session
Resources:
Abstract
74P - Real-world impact of adjuvant anti-PD-1 therapy on survival in Danish resected stage III melanoma patients
Presenter: Marie Weitemeyer
Session: Poster Display session
Resources:
Abstract
75P - Real-world data of adebrelimab in the first-line treatment of patients with small cell lung cancer
Presenter: Yong Song
Session: Poster Display session
Resources:
Abstract